Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...
Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...
Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...
Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...
Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...
Medpage Today on MSN12dOpinion
CMS Moved to Expand Obesity Drug Coverage. Private Insurers Need to Step Up.This proposed rule signals an important shift in the federal approach to obesity management, aligning with the medical ...
A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback